AN2 Therapeutics Inc./$ANTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
Ticker
$ANTX
Sector
Primary listing
Employees
21
Headquarters
Website
ANTX Metrics
BasicAdvanced
$171m
-
-$1.11
-
-
Price and volume
Market cap
$171m
52-week high
$6.91
52-week low
$1.00
Average daily volume
222k
Financial strength
Current ratio
15.73
Quick ratio
15.334
Profitability
Management effectiveness
Return on assets (TTM)
-27.48%
Return on equity (TTM)
-44.56%
Valuation
Price to book
2.09
Price to tangible book (TTM)
2.09
Price to free cash flow (TTM)
-4.73
Free cash flow yield (TTM)
-21.14%
Free cash flow per share (TTM)
-1.002
Growth
Earnings per share change (TTM)
-27.03%
3-year earnings per share growth (CAGR)
-23.86%
ANTX News
AllArticlesVideos
AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
Business Wire·2 weeks ago
AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
Business Wire·4 weeks ago
AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs